|
Abnormal dermatoglyphic pattern
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormality of radial ray
|
0.300 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
|
|
|
|
Abnormality of the nasopharynx
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormality of the skeletal system
|
0.020 |
Biomarker
|
disease |
BEFREE |
Involvement of SALL4 in cardiac malformations and NFATC2 gene disruption in both cardiac and skeletal anomalies are discussed.
|
24486774 |
2014 |
|
Abnormality of the skeletal system
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We describe a 0.73 Mb duplication of chromosome 22q11.21 between LCR-B and LCR-D and a missense mutation in a conserved C2H2 zinc finger domain of SALL4 in a cognitively normal patient with multiple skeletal anomalies including radioulnar synostosis, thumb aplasia, butterfly vertebrae, rib abnormalities, and hypoplasia of the humeral and femoral epiphyses.
|
25823593 |
2015 |
|
Absent radius
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia.
|
16998462 |
2006 |
|
Acute Undifferentiated Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our studies provide a foundation in the development of leukemia stem cell-specific therapy by targeting SALL4.
|
18487508 |
2008 |
|
Addictive Behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide.
|
29976840 |
2018 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
BEFREE |
LIN28 and SALL4 staining was seen in 2/52 (4%) and 14/52 (27%) gastric conventional adenocarcinomas, respectively.
|
30196987 |
2018 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
BEFREE |
The fetal gut-like adenocarcinoma component revealed diffuse immunoreactivity for SALL4 and partial positivity for AFP, whereas the conventional-type adenocarcinoma component was negative.
|
28970139 |
2017 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry showed the adenocarcinoma and primitive tubules to be strongly SALL4 and epithelial marker positive but with only focal expression of α-fetoprotein and glypican-3.
|
28315695 |
2017 |
|
Adenocarcinoma, Clear Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Loss of E-cadherin and fascin expression was significantly more frequent in UCE/DCEs than high-grade endometrioid and clear cell adenocarcinomas (P = 0.012, 0.014 and P = 0.01, 0.003, respectively).We suggest that loss of E-cadherin expression together with fascin and SALL4 immunopositivity in addition to morphologic features have an impact in differential diagnosis of UCE/DCEs from other high-grade endometrial carcinomas.
|
28272224 |
2017 |
|
Adult Acute Myeloblastic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Through immunohistochemistry and real-time reverse-transcription-polymerase chain reaction (RT-PCR), we demonstrated that SALL4 was constitutively expressed in human primary acute myeloid leukemia (AML, n = 81), and directly tested the leukemogenic potential of constitutive expression of SALL4 in a murine model.
|
16763212 |
2006 |
|
Adult Germ Cell Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
For CTC detection, a combination of germ cell tumor (anti-SALL4, anti-OCT3/4) and epithelial cell-specific (anti-keratin, anti-EpCAM) antibodies was used.
|
24634372 |
2014 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The present study aimed to investigate the function of SALL4 in U251 human glioblastoma cells, including apoptosis and invasion inhibition.
|
28943937 |
2017 |
|
Adult Liver Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, identification of a role of the exosomal SALL4/miR-146a-5p regulatory axis in M2-polarization as well as HCC progression provides potential targets for therapeutic and diagnostic applications in liver cancer.
|
31143524 |
2019 |
|
Adult Liver Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We developed a stringent high-throughput screening platform comprising unmodified SNU-387 and SNU-398 liver cancer cell lines and SNU-387 cell lines engineered to express low and high levels of SALL4.
|
31446059 |
2019 |
|
Adult Myelodysplastic Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Aberrant hypomethylation of SALL4 gene in patients with myelodysplastic syndrome.
|
23122807 |
2013 |
|
Adult Yolk Sac Tumor
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The intestinal-type mucinous glands were immunoreactive for SALL4 (4 cases), AFP (4 cases), glypican 3 (1 case), CDX2 (6 cases), and villin (7 cases), markers that are commonly expressed in YSTs, although the latter 2 markers would be expected to be positive in intestinal-type glands.
|
28582340 |
2018 |
|
Adult Yolk Sac Tumor
|
0.020 |
Biomarker
|
disease |
BEFREE |
Yolk sac tumor areas in the Group 1 cases were consistently immunoreactive for SALL4 and Glypican-3; variably positive for AFP (89%), Villin (89%), PLAP (78%), 34βE12 (67%), CAM 5.2 (62.5%), EMA (56%), CD117 (50%), p16 (50%), CDX2 (44%), p53 (44% aberrant), MOC31 (37.5%), CK7 (33%), GATA3 (33%), CK5 (25%), and PAX8 (11%); and were negative for CD30, Napsin A, OCT4, estrogen, androgen, and progesterone receptors.
|
31375771 |
2019 |
|
Agenesis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
An atypical 0.73 MB microduplication of 22q11.21 and a novel SALL4 missense mutation associated with thumb agenesis and radioulnar synostosis.
|
25823593 |
2015 |
|
Anal Stenosis, CTCAE
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
While the expression of SALL4 is normally restricted to ESCs and somatic stem cells, we found that it is aberrantly expressed in ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), a type of lymphoid malignancy carrying a mature T-cell immunophenotype. shRNA knockdown of SALL4 in ALK+ ALCL cell lines resulted in apoptosis and cell-cycle arrest, and significantly decreased colony formation on soft agar.
|
22743134 |
2012 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, SALL4 might be a promising marker for PDAC treatment and targeting SALL4 would benefit anti-proliferative and anti-metastasis therapies.
|
29958885 |
2018 |